Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
RMD Open
|
May 9, 2024
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Martin Rudwaleit, Atul Deodhar, Lars Bauer, et al.
Parkinsonism & Related Disorders
|
May 14, 2016
Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study
Zhen-Xin Zhang, Hui-Fang Shang, Xingyue Hu, et al.
BMC Neurology
|
April 17, 2015
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study
Jong-Min Kim, Sun Ju Chung, Jae Woo Kim, et al.
Expert Opinion on Pharmacotherapy
|
April 8, 2015
Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study
Sun Ju Chung, Jong-Min Kim, Jae Woo Kim, et al.
Mediterranean Journal of Rheumatology
|
September 21, 2022
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study
Gkikas Katsifis, Athina Theodoridou, Andreas Bounas, et al.
RMD Open
|
August 29, 2024
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis
Martin Rudwaleit, Helena Marzo-Ortega, Victoria Navarro-Compán, et al.
Rheumatology (Oxford, England)
|
June 26, 2020
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe
Xenofon Baraliakos, Torsten Witte, Luc De Clerck, et al.
Rheumatology and Therapy
|
September 30, 2022
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
Irene E van der Horst-Bruinsma, Philip C Robinson, Ennio G Favalli, et al.
Parkinsonism & Related Disorders
|
August 23, 2017
Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study
Zhen-Xin Zhang, Chun-Feng Liu, En-Xiang Tao, et al.
ACR Open Rheumatology
|
June 23, 2022
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study
Philip C Robinson, Walter P Maksymowych, Lianne S Gensler, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
RMD Open
|
May 9, 2024
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Martin Rudwaleit, Atul Deodhar, Lars Bauer, et al.
Parkinsonism & Related Disorders
|
May 14, 2016
Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study
Zhen-Xin Zhang, Hui-Fang Shang, Xingyue Hu, et al.
BMC Neurology
|
April 17, 2015
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study
Jong-Min Kim, Sun Ju Chung, Jae Woo Kim, et al.
Expert Opinion on Pharmacotherapy
|
April 8, 2015
Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study
Sun Ju Chung, Jong-Min Kim, Jae Woo Kim, et al.
Mediterranean Journal of Rheumatology
|
September 21, 2022
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study
Gkikas Katsifis, Athina Theodoridou, Andreas Bounas, et al.
RMD Open
|
August 29, 2024
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis
Martin Rudwaleit, Helena Marzo-Ortega, Victoria Navarro-Compán, et al.
Rheumatology (Oxford, England)
|
June 26, 2020
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe
Xenofon Baraliakos, Torsten Witte, Luc De Clerck, et al.
Rheumatology and Therapy
|
September 30, 2022
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
Irene E van der Horst-Bruinsma, Philip C Robinson, Ennio G Favalli, et al.
Parkinsonism & Related Disorders
|
August 23, 2017
Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study
Zhen-Xin Zhang, Chun-Feng Liu, En-Xiang Tao, et al.
ACR Open Rheumatology
|
June 23, 2022
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study
Philip C Robinson, Walter P Maksymowych, Lianne S Gensler, et al.
Page
of 5